why choose us

First received: January 24, 2023

Clinical Trial: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Thrombotic Thrombocytopenic Purpura (TTP)

Study Type: INTERVENTIONAL


Official Title: A Phase 2b, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of TAK-755 (rADAMTS13) With Minimal to No Plasma Exchange (PEX) in the Treatment of Immune-mediated Thrombotic Thrombocyt

Brief Summary: This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP).The main aim of this study is to determine the percentage of participants with a clinical response without plasma exchange during the study.Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response.Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute…

Read more